Alphamab Oncology

Sustainability Report and Carbon Intensity Rankings

Is Alphamab Oncology doing their part?

Their DitchCarbon score is 32

Alphamab Oncology has a DitchCarbon Score of 32 out of 100, indicating a lower performance in sustainability measures. This score suggests that the company has a relatively high carbon intensity compared to more sustainable peers. Efforts to reduce emissions and improve sustainability practices are needed to increase their score.

This was calculated based on 30+ company specific emissions data points, the higher the score, the better. Check out our methodology.

Industry emissions intensity

Very low




Very high

Alphamab Oncology is part of the health and social services industry, which has a low carbon intensity ranking compared to other industries. Some industries are more damaging than others, this ranking gives you an indication of how carbon intensive the industry is which this company operates in.

Location emissions intensity

Very low




Very high

Alphamab Oncology is situated in China, a region with a carbon intensity rating that influences the company’s environmental impact. The sustainability efforts of the company are affected by China’s national strategies and policies on carbon emissions.

...this company is doing 9.56% worse in emissions than the industry average.

Alphamab Oncology, founded in 2015, is a biopharmaceutical company based in China that specializes in the research, development, production, and commercialization of innovative oncology drugs. The company made its debut on the Hong Kong Stock Exchange on December 12, 2019, under the stock code 9966. Operating within the health and social services industry, Alphamab Oncology is dedicated to advancing cancer treatment options.

Bad news, Alphamab Oncology hasn't committed to SBTi goals yet.

Alphamab Oncology has not yet established specific commitments with the Science Based Targets initiative (SBTi). This means the company is still in the process of defining its goals for reducing greenhouse gas emissions in line with climate science.

There’s always room for improvement,

DitchCarbon recommends...

Alphamab Oncology should undertake a thorough inventory of all Scope 1 emissions sources and pursue energy efficiency improvements throughout its operations, while also shifting to low-carbon or renewable energy sources to potentially reduce emissions by 15%.
Not participating

Get unlimited free access to SBTI data via API

Reduce emissions with actionable insights on all your suppliers, embedded seamlessly into your procurement stack

Case study — How Compleat's clients use our carbon data

Making Compleat’s customers climate heroes. Download the 19-page case study PDF.

Claim this profile

Are you associate with this company?
Help us improve our data and claim this profile.

Our methodology

Read about our emission calculation methodologies, and what the DitchCarbon Score means.